Amgen wins drug patent case against Sanofi and Regeneron
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
List view / Grid view
17 March 2016 | By Victoria White
A jury has delivered a verdict in Amgen's favour in a trial on the validity of two Amgen patents that describe and claim monoclonal antibodies to PCSK9...
16 March 2016 | By Victoria White
NICE says there is not enough evidence to be able to say whether talimogene laherparepvec is as effective as other drugs used to treat advanced melanoma...
16 March 2016 | By Victoria White
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumour peptides...
16 March 2016 | By Victoria White
Absorb is a first-of-its-kind bioresorbable device for the treatment of coronary artery disease. It dissolves completely after 2 to 3 years...
15 March 2016 | By Tecan
Researchers at the Complutense University of Madrid are using directed evolution techniques to develop new enzymes for a variety of bioprocessing applications...
15 March 2016 | By Quotient Clinical
Quotient Clinical has announced the completion of its first clinical program involving Japanese healthy volunteers...
15 March 2016 | By Victoria White
The study met its primary objective, with nebulised RPL554 demonstrating a dose-dependent bronchodilator response in asthma patients...
15 March 2016 | By Victoria White
According to GlobalData analysts, hopes for improved therapies for glioblastoma have turned to Opdivo and drugs combining peptide vaccines with immuno-oncology products...
15 March 2016 | By Victoria White
Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer's dementia...
ReNeuron has demonstrated that its Human Retinal Progenitor Cells (hRPCs) improve visual acuity in preclinical models of retinal degeneration...
15 March 2016 | By Victoria White
The priority review is based on results of the IMvigor 210 study that evaluated the safety and efficacy of atezolizumab in people with locally advanced or metastatic urothelial carcinoma, regardless of PD-L1 expression.
15 March 2016 | By Victoria White
A real-world study showed use of Invokana (canagliflozin) is associated with significantly greater improvements in blood glucose control compared to DPP-4 inhibitors...
14 March 2016 | By Black Swan Analysis
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month...
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will be on Stand 12 at the upcoming Med-Tech Innovation Expo at the Ricoh Arena in Coventry, April 20-21...
14 March 2016 | By Wickham Laboratories Ltd
Wickham Laboratories Ltd will exhibit on Stand 307 at Making Pharmaceuticals, April 26-27...